Linkers unleashed: optimizing stability, release, and selectivity in conjugate design

Wednesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Linkers unleashed: optimizing stability, release, and selectivity in conjugate design

Linker design sits at the heart of bioconjugate performance. The choice between cleavable and non-cleavable architectures, and between pH-sensitive, enzyme-responsive, and other release mechanisms, directly determines pharmacokinetics, DAR, and the extent of bystander activity. Getting these decisions right is critical across ADCs and the broader bioconjugate landscape.

This expert panel brings together specialists from across the field to examine how linker strategies differ and converge across modalities, and what the latest thinking reveals about optimizing stability, controlled release, and target selectivity.

Attend this webinar to:

Understand the functional trade-offs between cleavable and non-cleavable linkers and how release mechanism selection affects payload delivery and therapeutic window
Explore how pH-sensitive and enzyme-responsive linker strategies improve selectivity and control release kinetics in the tumor microenvironment
Learn how bystander effect considerations should inform linker selection for heterogeneous tumor targets across conjugate modalities
Hear expert perspectives on how bystander effect considerations factor into linker selection and the implications for efficacy and safety across different tumor microenvironments